archive-com.com » COM » E » ENDEAVOURVISION.COM

Total: 462

Choose link from "Titles, links and description words view":

Or switch to "Titles and links view".
  • Recent news: BIND Therapeutics Appoints Andrew Hirsch as Acting President and Chief Executive Officer
    Fierce 15 Biotech Companies of 2014 September 12 2014 Symetis Receives CE Mark Approval for Transfemoral Transcatheter Aortic Heart Valve System ACURATE neo and Launches Product With First Commercial Implantations September 2 2014 Sophia Genetics Becomes the First European Company to Obtain CE IVD Mark for Clinical use of Next Generation Sequencing Bioinformatics Pipeline for Routine Genetic Testing July 8 2014 Sophia Genetics raises Series B round led by Invoke Capital July 1 2014 Stage 3 Phase 2 study of DARPin abicipar pegol previously MP0112 supports progressing to phase III development program June 19 2014 Bind Therapeutics enters nanomedicine collaboration with Swiss drug giant April 10 2014 CeQur Appoints Douglas Lawrence Chief Executive Officer April 8 2014 Epigenetic Cancer Therapy Clears Phase I March 5 2014 Diabetes Care Publishes Data Demonstrating PaQ Insulin Delivery Device Could Help People with Type 2 Diabetes Overcome Barriers to Insulin Adherence and Improve Clinical Outcomes January 8 2014 CeQur to Present at the 32nd Annual J P Morgan Healthcare Conference December 4 2013 Roche and Molecular Partners enter into alliance to develop new cancer treatments October 28 2013 Symetis Announces a Symbolic Milestone the 1000th Patient Implanted with ACURATE TA October 28 2013 French Cost Effectiveness Trial of PneumRx RePneu LVR Coil Fully Enrolled in Record Time September 26 2013 Symetis and Endoluminal Sciences enter into a license agreement to develop 3rd generation TAVI September 24 2013 Data Demonstrating Potential Benefits of Simple Insulin Delivery Device Presented at European Association for the Study of Diabetes Annual Meeting September 19 2013 BIND Therapeutics Announces Pricing of Initial Public Offering September 9 2013 CeQur SA Closes 27 Million Series B Financing August 27 2013 BIND Recognized by the World Economic Forum as a Technology Pioneer August 19 2013 BIND Doses First Patient in a Phase 2 Clinical Study of BIND 014 in Prostate Cancer August 12 2013 BIND Therapeutics Files Registration Statement for Proposed Initial Public Offering August 12 2013 Symetis announces successful first time implantation of i ts ACURATE TA and ACURATE TF TAVI systems in Japan April 3 2013 Symetis ACURATE TA TM Confirms Superior Results February 23 2011 BIND Biosciences named one of MIT s Technology Review 2011 TR50 second year in a row April 13 2010 CeQur SA names Robert O Holla EVP for Regulatory Affairs CAMBRIDGE Mass BUSINESS WIRE BIND Therapeutics Inc NASDAQ BIND a clinical stage nanomedicine platform company developing targeted and programmable therapeutics called Accurins today announced that Andrew Hirsch has been appointed the acting president and chief executive officer of the Company Mr Hirsch was formerly BIND s chief operating officer and chief financial officer and replaces Scott Minick who will remain a member of BIND s Board of Directors BIND intends to announce a permanent CEO following an expeditious evaluation of internal and external candidates BIND is well positioned to continue as a leader in nanomedicine and we are excited to have Andrew take on this important leadership role at BIND said Daniel Lynch Chairman of BIND

    Original URL path: http://www.endeavourvision.com/news-n249-c0-s22-BIND+Therapeutics+Appoints+Andrew+Hirsch.htm (2016-04-25)
    Open archived version from archive


  • Recent news: Merck Acquires OncoEthix, a Privately Held Oncology Company Developing Novel BET Inhibitors for Hematological and Solid Cancers
    as one of its Fierce 15 Biotech Companies of 2014 September 12 2014 Symetis Receives CE Mark Approval for Transfemoral Transcatheter Aortic Heart Valve System ACURATE neo and Launches Product With First Commercial Implantations September 2 2014 Sophia Genetics Becomes the First European Company to Obtain CE IVD Mark for Clinical use of Next Generation Sequencing Bioinformatics Pipeline for Routine Genetic Testing July 8 2014 Sophia Genetics raises Series B round led by Invoke Capital July 1 2014 Stage 3 Phase 2 study of DARPin abicipar pegol previously MP0112 supports progressing to phase III development program June 19 2014 Bind Therapeutics enters nanomedicine collaboration with Swiss drug giant April 10 2014 CeQur Appoints Douglas Lawrence Chief Executive Officer April 8 2014 Epigenetic Cancer Therapy Clears Phase I March 5 2014 Diabetes Care Publishes Data Demonstrating PaQ Insulin Delivery Device Could Help People with Type 2 Diabetes Overcome Barriers to Insulin Adherence and Improve Clinical Outcomes January 8 2014 CeQur to Present at the 32nd Annual J P Morgan Healthcare Conference December 4 2013 Roche and Molecular Partners enter into alliance to develop new cancer treatments October 28 2013 Symetis Announces a Symbolic Milestone the 1000th Patient Implanted with ACURATE TA October 28 2013 French Cost Effectiveness Trial of PneumRx RePneu LVR Coil Fully Enrolled in Record Time September 26 2013 Symetis and Endoluminal Sciences enter into a license agreement to develop 3rd generation TAVI September 24 2013 Data Demonstrating Potential Benefits of Simple Insulin Delivery Device Presented at European Association for the Study of Diabetes Annual Meeting September 19 2013 BIND Therapeutics Announces Pricing of Initial Public Offering September 9 2013 CeQur SA Closes 27 Million Series B Financing August 27 2013 BIND Recognized by the World Economic Forum as a Technology Pioneer August 19 2013 BIND Doses First Patient in a Phase 2 Clinical Study of BIND 014 in Prostate Cancer August 12 2013 BIND Therapeutics Files Registration Statement for Proposed Initial Public Offering August 12 2013 Symetis announces successful first time implantation of i ts ACURATE TA and ACURATE TF TAVI systems in Japan April 3 2013 Symetis ACURATE TA TM Confirms Superior Results February 23 2011 BIND Biosciences named one of MIT s Technology Review 2011 TR50 second year in a row April 13 2010 CeQur SA names Robert O Holla EVP for Regulatory Affairs Acquisition Expands Merck s Oncology Portfolio with Novel Oral BET Inhibitor OTX015 KENILWORTH N J Dec 18 2014 Merck NYSE MRK known as MSD outside the United States and Canada announced today that it has acquired through a subsidiary OncoEthix a Swiss based privately held biotechnology company specializing in oncology drug development Through the acquisition Merck has gained an investigational novel oral BET bromodomain inhibitor OTX015 which is currently in Phase 1b studies for the treatment of hematological malignancies and advanced solid tumors Oncology is a priority area of focus for Merck and the acquisition of OncoEthix supports our strategy to prioritize the development of innovative molecules with the potential to improve

    Original URL path: http://www.endeavourvision.com/news-n246-c0-s22-Merck+Acquires+OncoEthix%2C+a+Privately+.htm (2016-04-25)
    Open archived version from archive

  • Recent news: Total offer size of IPO reaches CHF 106.2 million after partial exercise of IPO over-allotment option
    CE Mark Approval for Transfemoral Transcatheter Aortic Heart Valve System ACURATE neo and Launches Product With First Commercial Implantations September 2 2014 Sophia Genetics Becomes the First European Company to Obtain CE IVD Mark for Clinical use of Next Generation Sequencing Bioinformatics Pipeline for Routine Genetic Testing July 8 2014 Sophia Genetics raises Series B round led by Invoke Capital July 1 2014 Stage 3 Phase 2 study of DARPin abicipar pegol previously MP0112 supports progressing to phase III development program June 19 2014 Bind Therapeutics enters nanomedicine collaboration with Swiss drug giant April 10 2014 CeQur Appoints Douglas Lawrence Chief Executive Officer April 8 2014 Epigenetic Cancer Therapy Clears Phase I March 5 2014 Diabetes Care Publishes Data Demonstrating PaQ Insulin Delivery Device Could Help People with Type 2 Diabetes Overcome Barriers to Insulin Adherence and Improve Clinical Outcomes January 8 2014 CeQur to Present at the 32nd Annual J P Morgan Healthcare Conference December 4 2013 Roche and Molecular Partners enter into alliance to develop new cancer treatments October 28 2013 Symetis Announces a Symbolic Milestone the 1000th Patient Implanted with ACURATE TA October 28 2013 French Cost Effectiveness Trial of PneumRx RePneu LVR Coil Fully Enrolled in Record Time September 26 2013 Symetis and Endoluminal Sciences enter into a license agreement to develop 3rd generation TAVI September 24 2013 Data Demonstrating Potential Benefits of Simple Insulin Delivery Device Presented at European Association for the Study of Diabetes Annual Meeting September 19 2013 BIND Therapeutics Announces Pricing of Initial Public Offering September 9 2013 CeQur SA Closes 27 Million Series B Financing August 27 2013 BIND Recognized by the World Economic Forum as a Technology Pioneer August 19 2013 BIND Doses First Patient in a Phase 2 Clinical Study of BIND 014 in Prostate Cancer August 12 2013 BIND Therapeutics Files Registration Statement for Proposed Initial Public Offering August 12 2013 Symetis announces successful first time implantation of i ts ACURATE TA and ACURATE TF TAVI systems in Japan April 3 2013 Symetis ACURATE TA TM Confirms Superior Results February 23 2011 BIND Biosciences named one of MIT s Technology Review 2011 TR50 second year in a row April 13 2010 CeQur SA names Robert O Holla EVP for Regulatory Affairs Zurich Schlieren December 5 2014 Molecular Partners AG announces that the total offer size of the initial public offering IPO amounts to CHF 106 2 million of which gross proceeds from the primary shares issued are CHF 104 1 million The Joint Bookrunners of Molecular Partners IPO have partially exercised the over allotment option yesterday at the offer price of CHF 22 40 per share Including the exercise of the over allotment option of 340 140 new registered shares the IPO resulted in the issuance of a total of 4 740 140 shares corresponding to 24 1 of the share capital The aggregate number of shares in issue after the partial exercise of the over allotment option is 19 640 140 registered shares with a nominal value

    Original URL path: http://www.endeavourvision.com/news-n245-c0-s22-Total+offer+size+of+IPO+reaches+CHF+106..htm (2016-04-25)
    Open archived version from archive

  • Recent news: PneumRx Acquired by BTG plc for up to USD 475 Million
    one of its Fierce 15 Biotech Companies of 2014 September 12 2014 Symetis Receives CE Mark Approval for Transfemoral Transcatheter Aortic Heart Valve System ACURATE neo and Launches Product With First Commercial Implantations September 2 2014 Sophia Genetics Becomes the First European Company to Obtain CE IVD Mark for Clinical use of Next Generation Sequencing Bioinformatics Pipeline for Routine Genetic Testing July 8 2014 Sophia Genetics raises Series B round led by Invoke Capital July 1 2014 Stage 3 Phase 2 study of DARPin abicipar pegol previously MP0112 supports progressing to phase III development program June 19 2014 Bind Therapeutics enters nanomedicine collaboration with Swiss drug giant April 10 2014 CeQur Appoints Douglas Lawrence Chief Executive Officer April 8 2014 Epigenetic Cancer Therapy Clears Phase I March 5 2014 Diabetes Care Publishes Data Demonstrating PaQ Insulin Delivery Device Could Help People with Type 2 Diabetes Overcome Barriers to Insulin Adherence and Improve Clinical Outcomes January 8 2014 CeQur to Present at the 32nd Annual J P Morgan Healthcare Conference December 4 2013 Roche and Molecular Partners enter into alliance to develop new cancer treatments October 28 2013 Symetis Announces a Symbolic Milestone the 1000th Patient Implanted with ACURATE TA October 28 2013 French Cost Effectiveness Trial of PneumRx RePneu LVR Coil Fully Enrolled in Record Time September 26 2013 Symetis and Endoluminal Sciences enter into a license agreement to develop 3rd generation TAVI September 24 2013 Data Demonstrating Potential Benefits of Simple Insulin Delivery Device Presented at European Association for the Study of Diabetes Annual Meeting September 19 2013 BIND Therapeutics Announces Pricing of Initial Public Offering September 9 2013 CeQur SA Closes 27 Million Series B Financing August 27 2013 BIND Recognized by the World Economic Forum as a Technology Pioneer August 19 2013 BIND Doses First Patient in a Phase 2 Clinical Study of BIND 014 in Prostate Cancer August 12 2013 BIND Therapeutics Files Registration Statement for Proposed Initial Public Offering August 12 2013 Symetis announces successful first time implantation of i ts ACURATE TA and ACURATE TF TAVI systems in Japan April 3 2013 Symetis ACURATE TA TM Confirms Superior Results February 23 2011 BIND Biosciences named one of MIT s Technology Review 2011 TR50 second year in a row April 13 2010 CeQur SA names Robert O Holla EVP for Regulatory Affairs MOUNTAIN VIEW Calif Dec 4 2014 PRNewswire PneumRx Inc www pneumrx com a leader in the field of interventional pulmonology today announced that it has signed an agreement to be acquired by BTG Plc LSE BTG in a deal worth up to 475 million based on an initial consideration of 230 million and up to 245 million in performance related milestone payments Based in London BTG is an international specialist healthcare company that is active in interventional medicine and specialty pharmaceuticals Their current interventional portfolio includes site specific treatments for severe blood clots including pulmonary embolisms liver tumors and varicose veins These therapies are differentiated minimally invasive and marketed to specialist physician groups

    Original URL path: http://www.endeavourvision.com/news-n244-c0-s22-PneumRx+Acquired+by+BTG+plc+for+up+to+US.htm (2016-04-25)
    Open archived version from archive

  • Recent news: Molecular Partners has successfully priced its IPO post re-launch and lists its shares on SIX Swiss Exchange
    Fierce 15 Biotech Companies of 2014 September 12 2014 Symetis Receives CE Mark Approval for Transfemoral Transcatheter Aortic Heart Valve System ACURATE neo and Launches Product With First Commercial Implantations September 2 2014 Sophia Genetics Becomes the First European Company to Obtain CE IVD Mark for Clinical use of Next Generation Sequencing Bioinformatics Pipeline for Routine Genetic Testing July 8 2014 Sophia Genetics raises Series B round led by Invoke Capital July 1 2014 Stage 3 Phase 2 study of DARPin abicipar pegol previously MP0112 supports progressing to phase III development program June 19 2014 Bind Therapeutics enters nanomedicine collaboration with Swiss drug giant April 10 2014 CeQur Appoints Douglas Lawrence Chief Executive Officer April 8 2014 Epigenetic Cancer Therapy Clears Phase I March 5 2014 Diabetes Care Publishes Data Demonstrating PaQ Insulin Delivery Device Could Help People with Type 2 Diabetes Overcome Barriers to Insulin Adherence and Improve Clinical Outcomes January 8 2014 CeQur to Present at the 32nd Annual J P Morgan Healthcare Conference December 4 2013 Roche and Molecular Partners enter into alliance to develop new cancer treatments October 28 2013 Symetis Announces a Symbolic Milestone the 1000th Patient Implanted with ACURATE TA October 28 2013 French Cost Effectiveness Trial of PneumRx RePneu LVR Coil Fully Enrolled in Record Time September 26 2013 Symetis and Endoluminal Sciences enter into a license agreement to develop 3rd generation TAVI September 24 2013 Data Demonstrating Potential Benefits of Simple Insulin Delivery Device Presented at European Association for the Study of Diabetes Annual Meeting September 19 2013 BIND Therapeutics Announces Pricing of Initial Public Offering September 9 2013 CeQur SA Closes 27 Million Series B Financing August 27 2013 BIND Recognized by the World Economic Forum as a Technology Pioneer August 19 2013 BIND Doses First Patient in a Phase 2 Clinical Study of BIND 014 in Prostate Cancer August 12 2013 BIND Therapeutics Files Registration Statement for Proposed Initial Public Offering August 12 2013 Symetis announces successful first time implantation of i ts ACURATE TA and ACURATE TF TAVI systems in Japan April 3 2013 Symetis ACURATE TA TM Confirms Superior Results February 23 2011 BIND Biosciences named one of MIT s Technology Review 2011 TR50 second year in a row April 13 2010 CeQur SA names Robert O Holla EVP for Regulatory Affairs Zurich Schlieren November 4 2014 Molecular Partners AG has successfully re launched its Initial Public Offering IPO Due to strong interest and demand from both international and Swiss institutional and private investors Molecular Partners accelerated the timetable and closed the bookbuilding process yesterday Monday 5pm CET Molecular Partners AG has successfully allocated 4 400 000 shares with a nominal value of CHF 0 10 each to institutional Swiss and international investors as well as to private domestic investors The offer price of CHF 22 4 per offered registered share Offer Price implies a post money market capitalisation of approximately CHF485 million on a fully diluted basis prior to exercise of the over allotment option The shares

    Original URL path: http://www.endeavourvision.com/news-n241-c0-s22-Molecular+Partners+has+successfully+pric.htm (2016-04-25)
    Open archived version from archive

  • Recent news: BIND Therapeutics Announces Agreement with Merck to Develop Targeted Accurin™ Nanomedicines for Oncology
    Partners as one of its Fierce 15 Biotech Companies of 2014 September 12 2014 Symetis Receives CE Mark Approval for Transfemoral Transcatheter Aortic Heart Valve System ACURATE neo and Launches Product With First Commercial Implantations September 2 2014 Sophia Genetics Becomes the First European Company to Obtain CE IVD Mark for Clinical use of Next Generation Sequencing Bioinformatics Pipeline for Routine Genetic Testing July 8 2014 Sophia Genetics raises Series B round led by Invoke Capital July 1 2014 Stage 3 Phase 2 study of DARPin abicipar pegol previously MP0112 supports progressing to phase III development program June 19 2014 Bind Therapeutics enters nanomedicine collaboration with Swiss drug giant April 10 2014 CeQur Appoints Douglas Lawrence Chief Executive Officer April 8 2014 Epigenetic Cancer Therapy Clears Phase I March 5 2014 Diabetes Care Publishes Data Demonstrating PaQ Insulin Delivery Device Could Help People with Type 2 Diabetes Overcome Barriers to Insulin Adherence and Improve Clinical Outcomes January 8 2014 CeQur to Present at the 32nd Annual J P Morgan Healthcare Conference December 4 2013 Roche and Molecular Partners enter into alliance to develop new cancer treatments October 28 2013 Symetis Announces a Symbolic Milestone the 1000th Patient Implanted with ACURATE TA October 28 2013 French Cost Effectiveness Trial of PneumRx RePneu LVR Coil Fully Enrolled in Record Time September 26 2013 Symetis and Endoluminal Sciences enter into a license agreement to develop 3rd generation TAVI September 24 2013 Data Demonstrating Potential Benefits of Simple Insulin Delivery Device Presented at European Association for the Study of Diabetes Annual Meeting September 19 2013 BIND Therapeutics Announces Pricing of Initial Public Offering September 9 2013 CeQur SA Closes 27 Million Series B Financing August 27 2013 BIND Recognized by the World Economic Forum as a Technology Pioneer August 19 2013 BIND Doses First Patient in a Phase 2 Clinical Study of BIND 014 in Prostate Cancer August 12 2013 BIND Therapeutics Files Registration Statement for Proposed Initial Public Offering August 12 2013 Symetis announces successful first time implantation of i ts ACURATE TA and ACURATE TF TAVI systems in Japan April 3 2013 Symetis ACURATE TA TM Confirms Superior Results February 23 2011 BIND Biosciences named one of MIT s Technology Review 2011 TR50 second year in a row April 13 2010 CeQur SA names Robert O Holla EVP for Regulatory Affairs CAMBRIDGE Mass BIND Therapeutics Inc NASDAQ BIND a clinical stage nanomedicine platform company developing targeted and programmable therapeutics called AccurinsTM today announced a joint research and development agreement with Merck known as MSD outside the United States and Canada through a subsidiary to discover and develop novel nanomedicines for oncology This collaboration will leverage BIND s proprietary nanomedicine technology to create targeted Accurins based on novel potent payloads from Merck s preclinical oncology portfolio The first two Merck compounds include a kinesin spindle protein KSP inhibitor and a polo like kinase 1 PLK1 inhibitor Both KSP and PLK1 are regulators of cellular mitosis and are considered essential to the proliferation of

    Original URL path: http://www.endeavourvision.com/news-n242-c0-s22-BIND+Therapeutics+Announces+Agreement+wi.htm (2016-04-25)
    Open archived version from archive

  • Recent news: Sophia Genetics Adds Cystic Fibrosis Analysis to Clinical Bioinformatics Portfolio
    of its Fierce 15 Biotech Companies of 2014 September 12 2014 Symetis Receives CE Mark Approval for Transfemoral Transcatheter Aortic Heart Valve System ACURATE neo and Launches Product With First Commercial Implantations September 2 2014 Sophia Genetics Becomes the First European Company to Obtain CE IVD Mark for Clinical use of Next Generation Sequencing Bioinformatics Pipeline for Routine Genetic Testing July 8 2014 Sophia Genetics raises Series B round led by Invoke Capital July 1 2014 Stage 3 Phase 2 study of DARPin abicipar pegol previously MP0112 supports progressing to phase III development program June 19 2014 Bind Therapeutics enters nanomedicine collaboration with Swiss drug giant April 10 2014 CeQur Appoints Douglas Lawrence Chief Executive Officer April 8 2014 Epigenetic Cancer Therapy Clears Phase I March 5 2014 Diabetes Care Publishes Data Demonstrating PaQ Insulin Delivery Device Could Help People with Type 2 Diabetes Overcome Barriers to Insulin Adherence and Improve Clinical Outcomes January 8 2014 CeQur to Present at the 32nd Annual J P Morgan Healthcare Conference December 4 2013 Roche and Molecular Partners enter into alliance to develop new cancer treatments October 28 2013 Symetis Announces a Symbolic Milestone the 1000th Patient Implanted with ACURATE TA October 28 2013 French Cost Effectiveness Trial of PneumRx RePneu LVR Coil Fully Enrolled in Record Time September 26 2013 Symetis and Endoluminal Sciences enter into a license agreement to develop 3rd generation TAVI September 24 2013 Data Demonstrating Potential Benefits of Simple Insulin Delivery Device Presented at European Association for the Study of Diabetes Annual Meeting September 19 2013 BIND Therapeutics Announces Pricing of Initial Public Offering September 9 2013 CeQur SA Closes 27 Million Series B Financing August 27 2013 BIND Recognized by the World Economic Forum as a Technology Pioneer August 19 2013 BIND Doses First Patient in a Phase 2 Clinical Study of BIND 014 in Prostate Cancer August 12 2013 BIND Therapeutics Files Registration Statement for Proposed Initial Public Offering August 12 2013 Symetis announces successful first time implantation of i ts ACURATE TA and ACURATE TF TAVI systems in Japan April 3 2013 Symetis ACURATE TA TM Confirms Superior Results February 23 2011 BIND Biosciences named one of MIT s Technology Review 2011 TR50 second year in a row April 13 2010 CeQur SA names Robert O Holla EVP for Regulatory Affairs October 03 2014 By Uduak Grace Thomas NEW YORK GenomeWeb Sophia Genetics a clinical genomic data analysis services provider this week launched a new CE IVD marked software pipeline that lets clinical researchers identify and characterize genetic variants associated with cystic fibrosis using data from a single next generation sequencing experiment According to the company it s the first solution of this nature on the market and enables clinical labs to run fewer experiments than the status quo while still obtaining accurate results Jurgi Camblong co founder and CEO of Sophia Genetics told BioInform Current testing for CF mutations requires labs to sequence samples as well as run additional reflex and multiplex ligation dependent

    Original URL path: http://www.endeavourvision.com/news-n239-c0-s22-Sophia+Genetics+Adds+Cystic+Fibrosis+Ana.htm (2016-04-25)
    Open archived version from archive

  • Recent news: Molecular Partners launches IPO on SIX Swiss Exchange
    Biotech Companies of 2014 September 12 2014 Symetis Receives CE Mark Approval for Transfemoral Transcatheter Aortic Heart Valve System ACURATE neo and Launches Product With First Commercial Implantations September 2 2014 Sophia Genetics Becomes the First European Company to Obtain CE IVD Mark for Clinical use of Next Generation Sequencing Bioinformatics Pipeline for Routine Genetic Testing July 8 2014 Sophia Genetics raises Series B round led by Invoke Capital July 1 2014 Stage 3 Phase 2 study of DARPin abicipar pegol previously MP0112 supports progressing to phase III development program June 19 2014 Bind Therapeutics enters nanomedicine collaboration with Swiss drug giant April 10 2014 CeQur Appoints Douglas Lawrence Chief Executive Officer April 8 2014 Epigenetic Cancer Therapy Clears Phase I March 5 2014 Diabetes Care Publishes Data Demonstrating PaQ Insulin Delivery Device Could Help People with Type 2 Diabetes Overcome Barriers to Insulin Adherence and Improve Clinical Outcomes January 8 2014 CeQur to Present at the 32nd Annual J P Morgan Healthcare Conference December 4 2013 Roche and Molecular Partners enter into alliance to develop new cancer treatments October 28 2013 Symetis Announces a Symbolic Milestone the 1000th Patient Implanted with ACURATE TA October 28 2013 French Cost Effectiveness Trial of PneumRx RePneu LVR Coil Fully Enrolled in Record Time September 26 2013 Symetis and Endoluminal Sciences enter into a license agreement to develop 3rd generation TAVI September 24 2013 Data Demonstrating Potential Benefits of Simple Insulin Delivery Device Presented at European Association for the Study of Diabetes Annual Meeting September 19 2013 BIND Therapeutics Announces Pricing of Initial Public Offering September 9 2013 CeQur SA Closes 27 Million Series B Financing August 27 2013 BIND Recognized by the World Economic Forum as a Technology Pioneer August 19 2013 BIND Doses First Patient in a Phase 2 Clinical Study of BIND 014 in Prostate Cancer August 12 2013 BIND Therapeutics Files Registration Statement for Proposed Initial Public Offering August 12 2013 Symetis announces successful first time implantation of i ts ACURATE TA and ACURATE TF TAVI systems in Japan April 3 2013 Symetis ACURATE TA TM Confirms Superior Results February 23 2011 BIND Biosciences named one of MIT s Technology Review 2011 TR50 second year in a row April 13 2010 CeQur SA names Robert O Holla EVP for Regulatory Affairs Not for release publication or distribution in the United States of America Canada Australia or Japan For release in Switzerland only This is a restricted communication and you must not forward it or its contents to any person to whom forwarding it is prohibited by the legends contained therein In particular this release and the information contained therein is not being issued and may not be distributed in the United States of America Canada Australia or Japan and does not constitute an offer of securities for sale in such or any other countries Zurich Schlieren September 23 2014 Molecular Partners AG announced today its plans to list its shares on the SIX Swiss Exchange in the fourth quarter

    Original URL path: http://www.endeavourvision.com/news-n236-c0-s22-Molecular+Partners+launches+IPO+on+SIX+S.htm (2016-04-25)
    Open archived version from archive



  •